Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $430.84M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.67M
Average 1.21M
PHAT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Phathom Pharmaceuticals, Inc.NASDAQ: PHAT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $3.12M (cash outflow) fell 55.1% year over year, behind the +15.0% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +57.8% a year.
Context
- Accounts payables amounted to 19.5% of revenue in FY2025, down 43.8 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -55.1% toward the trailing-twelve-month pace of +15.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 34.1M USD
- Year-over-year change
- -2.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.1M | -2.4% |
| FY2024 | 2024-12-31 | 34.94M | +445.0% |
| FY2023 | 2023-12-31 | 6.41M | -26.1% |
| FY2022 | 2022-12-31 | 8.68M | +188.6% |
| FY2021 | 2021-12-31 | (9.79M) | — |
Accounts Payables vs competitors
How PHAT compares with its peers on the latest reported figures
- PHAT's LTM Mar 2026 accounts payables of $37.94M is the largest of the 2 companies compared; the peer median is $14.47M.
- Its year-over-year change of +15.0% is the lowest of 2, against a peer median of +507.1%.
- Accounts payables amounts to 18.5% of revenue for PHAT, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.94M | +15.0% | +57.8% | 18.5% | |
| LTM Mar 2026 | $14.47M | +507.1% | -21.1% | 3.4% | |
| Peer median (excluding PHAT) | $14.47M | +507.1% | -21.1% | 3.4% | |
Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Depreciation & Amortization | 521K | 620K | 575K | 795K | 633K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.81M | 24.13M | 45.03M | 24.05M | 28.72M |
| Change in Working Capital | (27.32M) | 5.44M | (13.64M) | (15.3M) | (12.38M) |
| Accounts Receivables | 0 | 0 | (1.64M) | (37.16M) | (39.33M) |
| Inventory | 0 | 0 | (9.44M) | (6.14M) | (11.78M) |
| Accounts Payables | (9.79M) | 8.68M | 6.41M | 34.94M | 34.1M |
| Other Working Capital | (17.52M) | (3.24M) | (8.98M) | (6.93M) | 4.63M |
| Other Non-Cash Items | 5.41M | 21M | 32.06M | 58.01M | 37.5M |
| Operating Cash Flow | (148.46M) | (146.53M) | (137.58M) | (266.77M) | (166.78M) |
| Capital Expenditures | (328K) | (1.04M) | (1.63M) | (135K) | (229K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (328K) | (1.04M) | (1.63M) | (135K) | (229K) |
| Debt Repayment | 42.76M | 95.45M | 39.32M | 59.4M | 0 |
| Common Stock Issued | 0 | 24.6M | 155.46M | 121.78M | 1.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 0 | 172.8M | 1.6M | (1.93M) |
| Financing Cash Flow | 44.71M | 120.04M | 367.58M | 182.77M | (288K) |
| Effect of Forex Changes | 0 | (345K) | 0 | 0 | 0 |
| Net Change in Cash | (104.08M) | (27.87M) | 228.37M | (84.13M) | (167.29M) |
| Free Cash Flow | (148.79M) | (147.57M) | (139.21M) | (266.91M) | (166.78M) |
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
Intrinsic Alpha fair value
Locked
Current Price
$5.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.